RdB + interleukin-12 + short hairpin vascular endothelial growth factor

RdB + interleukin-12 + short hairpin vascular endothelial growth factor is a combination experimental therapeutic platform envisioned for cancer treatment. It combines three components: - **RdB:** This typically refers to a recombinant oncolytic adenovirus (rAd or RdB), used as a vector to deliver gene payloads directly to tumor cells. - **interleukin-12:** A potent pro-inflammatory cytokine known to enhance cell-mediated immune responses, promote interferon-gamma production, and exhibit anti-tumor effects, partly through suppression of abnormal vascular growth and modulation of the tumor microenvironment[1]. - **short hairpin vascular endothelial growth factor (shVEGF):** A gene-silencing strategy using short hairpin RNA to knock down expression of vascular endothelial growth factor (VEGF), a key driver of angiogenesis in tumors, thereby inhibiting tumor blood vessel formation[2][6]. The combined mechanism is intended to simultaneously stimulate anti-tumor immunity (via IL-12), suppress tumor vasculature (via shVEGF), and maximize local delivery (via oncolytic adenoviral vector). Such multi-modal strategies are under investigation for solid tumors, aiming to inhibit tumor progression by blocking both angiogenesis and immune evasion.